Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTD26RC)

• DTT Name: Cell adhesion molecule (CADM)
• Gene Name: CADM
• DTT Type: Clinical trial target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T68039

Molecular Interaction Atlas (MIA) of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PRX003	DM5KI6X	Psoriasis vulgaris	EA90	Phase 1	[1]

7 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABX-MA1	DMZYVPB	Melanoma	2C30	Discontinued in Phase 1	[2]
ABS-205	DMALPDW	Neurodegenerative disorder	8A20-8A23	Terminated	[3]
CY-1748	DM0X147	Deep vein thrombosis	BD71	Terminated	[4]
GM-7050	DMEVIP9	Inflammation	1A00-CA43.1	Terminated	[5]
ICM-3	DMDBICR	Graft-versus-host disease	4B24	Terminated	[6]
NPC-17923	DMD01GK	Rheumatoid arthritis	FA20	Terminated	[7]
Rovelizumab	DM4VCJI	Cerebrovascular disease	8B2Z	Terminated	[8]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 2002 Sep 1;62(17):5106-14.
• [3] Drug Discovery and Development for Alzheimer's Disease, 2000. Page(21).
• [4] US patent application no. 6,492,332, Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation.
• [5] US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
• [6] Anti-tumor activity of an ICAM-3 antibody (ICM3) Against human leukemic xenograft tumors in nude mice. Volume 28, Issue 7, Supplement 1, 1 July 2000, Pages 59-60.
• [7] Inhibition of platelet-activating factor-induced leukocyte adhesion in vivo by a leumedin. Eur J Pharmacol. 1993 Mar 2;232(2-3):169-72.
• [8] Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6.